Novartis has powered Ayala Pharmaceuticals to a $30 million series B round. Ayala will use the cash to fund mid-phase development of pan-Notch inhibitor AL101 in adenoid cystic carcinoma (ACC).
Novartis powers Notch cancer biotech Ayala to $30M series B
![](http://ibf.fund/wp-content/uploads/2019/01/Team_0026_Layer-10-e1559140959990.png)